Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

(MedPage Today) — The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday.
Approval stipulates use of the combination, with or without bevacizumab, in adults…